Efficacy and safety of lidocaine vs. opioid analgesics in acute coronary syndromes
European Heart Journal. Acute Cardiovascular Care · 27.01.2023 · 12 (1) · 12-13
DOI: 10.1093/ehjacc/zuac157 ↗Kurz gefasst
Editorial in der Zeitschrift European Heart Journal. Acute Cardiovascular Care, online erschienen am 20.12.2022. Verfasst von Mattia Galli und 1 weiteren Autor:innen. Beteiligte Einrichtung: Catholic University of the Sacred Heart, Largo Francesco Vito, 1, 00168 Roma, Italy. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Myocardial Infarction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
This editorial refers to ‘LidocAine Versus Opioids In MyocarDial infarction: the AVOID-2 randomized controlled trial’, by H. Fernando et al., https://doi.org/10.1093/ehjacc/zuac154. Opioid analgesics are largely implemented for the relief of acute pain in several clinical settings, including among patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).1 However, opioid analgesics have several side effects, including nausea, vomiting, impaired gastrointestinal motility, hypotension, and respiratory depression. Moreover, the fundamental limitations of opioid analgesics are that they lead to relatively fast tolerance and dependence. For these reasons, the Centers for Disease Control and Prevention for Prescribing Opioids recommend that non-opioid therapies that are at least as effective as opioids be used for the management of acute pain, and that instead opioid drugs be considered only if the benefits are anticipated to outweigh the risks.2 Importantly, among patients with ACS, opioid analgesics have been associated with slower uptake and delayed onset of action of oral P2Y12 inhibitors leading to impaired platelet inhibition and increased rates of high platelet reactivity (HPR) in the hours that follow drug administration, potentially increasing the risk of acute thrombotic complications.3–5 This led the European Society of Cardiology guidelines on ST-segment elevation ACS (STE-ACS) to downgrade the recommendation on the use of opioid analgesics from Class I to IIa.1 The impact of opioid analgesics on absorption and onset of action of oral P2Y12 inhibitors fuelled interest towards investigations on the safety and efficacy of alternative, non-opioid, analgesic drugs for the treatment of chest pain.6–8 To this extent, based on promising results from early observational studies, lidocaine, a sodium channel blocker commonly used for local and regional anaesthesia, as well as an antiarrhythmic drug (Class Ic), has been proposed.9,10 The impact of intravenous lidocaine vs. fentanyl on platelet reactivity in patients with non-ST elevation ACS (NSTE-ACS) was assessed in the LOCAL trial.6 In this pharmacokinetic/pharmacodynamic study, 90 patients were randomized to either intravenous fentanyl or lidocaine and underwent integral ticagrelor tablet loading dose administration (180 mg) at the end of PCI. The primary endpoint of plasma ticagrelor levels at 2 h post-loading dose was significantly lower in the fentanyl than in the lidocaine arm, suggesting that lidocaine does not impair the bioavailability or delay the antiplatelet effect of ticagrelor.6 Although these pharmacokinetic findings translated into more favourable pharmacodynamic effects (i.e. enhanced platelet inhibition and lower HPR rates) among patients treated with lidocaine compared with those treated with fentanyl, this study was not powered for clinical outcomes and included patients at low baseline verbal pain scores (2 and 1 out of 10 in the fentanyl and lidocaine arms, respectively), falling short in demonstrating any meaningful impact on the key purpose of using such adjunctive therapies in ACS patients (i.e. chest pain relief).11 Against this background, the lidocAine Versus Opioids In MyocarDial Infarction (AVOID-2) study, the results of which are reported in this issue of the European Heart Journal: Acute Cardiovascular Care, was designed to fill this gap in evidence.12 In particular, this was a Phase II, pre-hospital, open-label, non-inferiority, randomized-controlled trial, conducted in patients with suspected STE-ACS (n = 308) and a verbal pain score of at least 5 out of 10. The patients were randomized to pre-hospital intravenous administration of either lidocaine or fentanyl. Patients allocated to lidocaine received a dose of 50 mg administered over 2 min if the patient’s weight was
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Catholic University of the Sacred Heart, Largo Francesco Vito, 1, 00168 Roma, Italy.
- GVM Care & Reaserch, Via Corriera, 1, 48033 Cotignola, Italy.
- Division of Cardiology, University of Florida College of Medicine, 655 West 8th Street, Jacksonville, FL 32209, USA.
ORCID-Profile: Mattia Galli, Dominick J Angiolillo
Zitieren
APA
Galli, M., & Angiolillo, D. J. (2023). Efficacy and safety of lidocaine vs. opioid analgesics in acute coronary syndromes. European Heart Journal. Acute Cardiovascular Care, 12(1), 12-13. https://doi.org/10.1093/ehjacc/zuac157
Vancouver
Galli M, Angiolillo DJ. Efficacy and safety of lidocaine vs. opioid analgesics in acute coronary syndromes. European Heart Journal. Acute Cardiovascular Care. 2023;12(1):12-13. doi:10.1093/ehjacc/zuac157
BibTeX
@article{Galli2023,
author = {Galli, Mattia and Angiolillo, Dominick J},
title = {Efficacy and safety of lidocaine vs. opioid analgesics in acute coronary syndromes},
journal = {European Heart Journal. Acute Cardiovascular Care},
year = {2023},
volume = {12},
number = {1},
pages = {12--13},
doi = {10.1093/ehjacc/zuac157}
}
EUVIMED